

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.0	28.09.2024	2091173-00016	Date of first issue: 17.10.2017

SECTION 1: Identification of the substance/mixture and of the company/undertaking**1.1 Product identifier**

Trade name : Buparvaquone Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised againstUse of the Sub-
stance/Mixture : Veterinary productRecommended restrictions
on use : Not applicable**1.3 Details of the supplier of the safety data sheet**Company : MSD
20 Spartan Road
1619 Spartan, South Africa

Telephone : +27119239300

E-mail address of person
responsible for the SDS : EHSDATASTEWARD@msd.com**1.4 Emergency telephone number**

+1-908-423-6000

SECTION 2: Hazards identification**2.1 Classification of the substance or mixture****Classification (REGULATION (EC) No 1272/2008)**

Skin irritation, Category 2	H315: Causes skin irritation.
Eye irritation, Category 2	H319: Causes serious eye irritation.
Reproductive toxicity, Category 1B	H360D: May damage the unborn child.
Specific target organ toxicity - single exposure, Category 3	H335: May cause respiratory irritation.
Short-term (acute) aquatic hazard, Category 1	H400: Very toxic to aquatic life.
Long-term (chronic) aquatic hazard, Category 1	H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements**Labelling (REGULATION (EC) No 1272/2008)**

Hazard pictograms :



Signal word : Danger

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.0	28.09.2024	2091173-00016	Date of first issue: 17.10.2017

Hazard statements : H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
H360D May damage the unborn child.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**
P201 Obtain special instructions before use.
P264 Wash skin thoroughly after handling.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
Response:
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P391 Collect spillage.

Hazardous components which must be listed on the label:

N-Methyl-2-pyrrolidone

Additional Labelling

Restricted to professional users.

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients**3.2 Mixtures****Components**

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
N-Methyl-2-pyrrolidone	872-50-4 212-828-1 606-021-00-7	Skin Irrit. 2; H315 Eye Irrit. 2; H319 Repr. 1B; H360D STOT SE 3; H335	>= 50 - < 70
Buparvaquone	88426-33-9	Eye Irrit. 2; H319 Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 10 M-Factor (Chronic aquatic toxicity): 10	>= 2,5 - < 10

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.0	28.09.2024	2091173-00016	Date of first issue: 17.10.2017

For explanation of abbreviations see section 16.

SECTION 4: First aid measures**4.1 Description of first aid measures**

- | | | |
|----------------------------|---|--|
| General advice | : | In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice. |
| Protection of first-aiders | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| If inhaled | : | If inhaled, remove to fresh air.
Get medical attention. |
| In case of skin contact | : | In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse. |
| In case of eye contact | : | In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention. |
| If swallowed | : | If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water. |

4.2 Most important symptoms and effects, both acute and delayed

- | | | |
|-------|---|--|
| Risks | : | Causes skin irritation.
Causes serious eye irritation.
May cause respiratory irritation.
May damage the unborn child. |
|-------|---|--|

4.3 Indication of any immediate medical attention and special treatment needed

- | | | |
|-----------|---|---|
| Treatment | : | Treat symptomatically and supportively. |
|-----------|---|---|

SECTION 5: Firefighting measures**5.1 Extinguishing media**

- | | | |
|------------------------------|---|--|
| Suitable extinguishing media | : | Water spray
Alcohol-resistant foam
Carbon dioxide (CO ₂)
Dry chemical |
|------------------------------|---|--|

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.0	28.09.2024	2091173-00016	Date of first issue: 17.10.2017

Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures**6.1 Personal precautions, protective equipment and emergency procedures**

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.0	28.09.2024	2091173-00016	Date of first issue: 17.10.2017

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

- | | | |
|-------------------------|---|---|
| Technical measures | : | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section. |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation. |
| Advice on safe handling | : | Do not get on skin or clothing.
Avoid breathing mist or vapours.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.
Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

7.2 Conditions for safe storage, including any incompatibilities

- | | | |
|---|---|--|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store locked up. Keep tightly closed. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations. |
| Advice on common storage | : | Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Explosives
Gases |

7.3 Specific end use(s)

- | | | |
|-----------------|---|-------------------|
| Specific use(s) | : | No data available |
|-----------------|---|-------------------|

Buparvaquone Formulation

Version 5.0 Revision Date: 28.09.2024 SDS Number: 2091173-00016 Date of last issue: 06.04.2024
 Date of first issue: 17.10.2017

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
N-Methyl-2-pyrrolidone	872-50-4	TWA	10 ppm 40 mg/m ³	2009/161/EU
		STEL	20 ppm 80 mg/m ³	2009/161/EU
		TWA	10 ppm 40 mg/m ³	2004/37/EC
		STEL	20 ppm 80 mg/m ³	2004/37/EC
Buparvaquone	88426-33-9	TWA	40 µg/m ³ (OEB 3)	Internal
		Wipe limit	400 µg/100 cm ²	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
N-Methyl-2-pyrrolidone	Workers	Inhalation	Long-term systemic effects	14,4 mg/m ³
	Workers	Inhalation	Long-term local effects	40 mg/m ³
	Workers	Skin contact	Long-term systemic effects	4,8 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	3,6 mg/m ³
	Consumers	Inhalation	Long-term local effects	4,5 mg/m ³
	Consumers	Skin contact	Long-term systemic effects	2,4 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	0,85 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
N-Methyl-2-pyrrolidone	Fresh water	0,25 mg/l
	Freshwater - intermittent	5 mg/l
	Marine water	0,025 mg/l
	Sewage treatment plant	10 mg/l
	Fresh water sediment	1,09 mg/kg dry weight (d.w.)
	Marine sediment	1,09 mg/kg dry weight (d.w.)
	Soil	0,07 mg/kg dry weight (d.w.)

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.0	28.09.2024	2091173-00016	Date of first issue: 17.10.2017

8.2 Exposure controls**Engineering measures**

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection		
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties**9.1 Information on basic physical and chemical properties**

Appearance	:	liquid
Colour	:	clear, red
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.0	28.09.2024	2091173-00016	Date of first issue: 17.10.2017

Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	1 (20 °C)
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids)	:	No data available
Particle size	:	Not applicable

SECTION 10: Stability and reactivity**10.1 Reactivity**

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions	:	Can react with strong oxidizing agents.
---------------------	---	---

10.4 Conditions to avoid

Conditions to avoid	:	None known.
---------------------	---	-------------

10.5 Incompatible materials

Materials to avoid	:	Oxidizing agents
--------------------	---	------------------

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.0	28.09.2024	2091173-00016	Date of first issue: 17.10.2017

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:

N-Methyl-2-pyrrolidone:

Acute oral toxicity	: LD50 (Rat): 4.150 mg/kg
Acute inhalation toxicity	: LC50 (Rat): > 5,1 mg/l Exposure time: 4 h Test atmosphere: dust/mist Method: OECD Test Guideline 403
Acute dermal toxicity	: LD50 (Rat): > 5.000 mg/kg

Buparvaquone:

Acute oral toxicity	: LD50 (Rat): > 8.000 mg/kg LD50 (Mouse): > 50 mg/kg Remarks: No mortality observed at this dose.
Acute toxicity (other routes of administration)	: LD50: 2,5 mg/kg Application Route: Intravenous

Skin corrosion/irritation

Causes skin irritation.

Components:

N-Methyl-2-pyrrolidone:

Result	: Skin irritation
--------	-------------------

Buparvaquone:

Species	: Mouse
Result	: Mild skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

N-Methyl-2-pyrrolidone:

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.0	28.09.2024	2091173-00016	Date of first issue: 17.10.2017

Species	: Rabbit
Result	: Irritation to eyes, reversing within 21 days

Buparvaquone:

Result	: Mild eye irritation
--------	-----------------------

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

N-Methyl-2-pyrrolidone:

Test Type	: Local lymph node assay (LLNA)
Exposure routes	: Skin contact
Species	: Mouse
Method	: OECD Test Guideline 429
Result	: negative
Remarks	: Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:

N-Methyl-2-pyrrolidone:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES)
	Method: OECD Test Guideline 471
	Result: negative
	Test Type: In vitro mammalian cell gene mutation test
	Method: OECD Test Guideline 476
	Result: negative
	Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
	Result: negative
	Genotoxicity in vivo
Species: Mouse	
Application Route: Ingestion	
Method: OECD Test Guideline 474	
Result: negative	
	Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
	Species: Hamster
	Application Route: Ingestion
	Method: OECD Test Guideline 475

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.0	28.09.2024	2091173-00016	Date of first issue: 17.10.2017

Result: negative

Carcinogenicity

Not classified based on available information.

Components:**N-Methyl-2-pyrrolidone:**

Species	: Rat
Application Route	: Ingestion
Exposure time	: 2 Years
Result	: negative

Species	: Rat
Application Route	: inhalation (vapour)
Exposure time	: 2 Years
Result	: negative

Reproductive toxicity

May damage the unborn child.

Components:**N-Methyl-2-pyrrolidone:**

Effects on fertility	: Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Ingestion Method: OECD Test Guideline 416 Result: negative
----------------------	--

Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Method: OECD Test Guideline 414 Result: positive
-------------------------------	---

	: Test Type: Fertility/early embryonic development Species: Rat Application Route: inhalation (vapour) Result: positive
--	--

	: Test Type: Embryo-foetal development Species: Rabbit Application Route: Ingestion Result: positive
--	---

Reproductive toxicity - Assessment	: Clear evidence of adverse effects on development, based on animal experiments.
------------------------------------	--

STOT - single exposure

May cause respiratory irritation.

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.0	28.09.2024	2091173-00016	Date of first issue: 17.10.2017

Components:**N-Methyl-2-pyrrolidone:**

Assessment : May cause respiratory irritation.

STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity**Components:****N-Methyl-2-pyrrolidone:**

Species : Rat, male
NOAEL : 169 mg/kg
LOAEL : 433 mg/kg
Application Route : Ingestion
Exposure time : 90 Days
Method : OECD Test Guideline 408

Species : Rat
NOAEL : 0,5 mg/l
LOAEL : 1 mg/l
Application Route : inhalation (dust/mist/fume)
Exposure time : 96 Days
Method : OECD Test Guideline 413

Species : Rabbit
NOAEL : 826 mg/kg
LOAEL : 1.653 mg/kg
Application Route : Skin contact
Exposure time : 20 Days

Buparvaquone:

Species : Cat
NOAEL : 10 mg/kg
Application Route : Intramuscular
Exposure time : 5 d
Remarks : No significant adverse effects were reported

NOAEL : 5 mg/kg
Application Route : Intravenous
Exposure time : 4 d
Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 6 d
Remarks : No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.0	28.09.2024	2091173-00016	Date of first issue: 17.10.2017

Experience with human exposure**Components:****N-Methyl-2-pyrrolidone:**

Skin contact	: Symptoms: Skin irritation
--------------	-----------------------------

SECTION 12: Ecological information**12.1 Toxicity****Components:****N-Methyl-2-pyrrolidone:**

Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 1.000 mg/l Exposure time: 24 h Method: DIN 38412
Toxicity to algae/aquatic plants	: ErC50 (Desmodesmus subspicatus (green algae)): 600,5 mg/l Exposure time: 72 h EC10 (Desmodesmus subspicatus (green algae)): 92,6 mg/l Exposure time: 72 h
Toxicity to microorganisms	: EC50 : > 600 mg/l Exposure time: 30 min Method: ISO 8192
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC: 12,5 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

Buparvaquone:

Toxicity to fish	: LC50 (Brachydanio rerio (zebrafish)): 0,484 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 0,013 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
M-Factor (Acute aquatic toxicity)	: 10
M-Factor (Chronic aquatic toxicity)	: 10

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.0	28.09.2024	2091173-00016	Date of first issue: 17.10.2017

12.2 Persistence and degradability**Components:****N-Methyl-2-pyrrolidone:**

Biodegradability	:	Result: Readily biodegradable. Biodegradation: 73 % Exposure time: 28 d Method: OECD Test Guideline 301C
------------------	---	---

12.3 Bioaccumulative potential**Components:****N-Methyl-2-pyrrolidone:**

Partition coefficient: n-octanol/water	:	log Pow: -0,46 Method: OECD Test Guideline 107
--	---	---

Buparvaquone:

Partition coefficient: n-octanol/water	:	log Pow: 6,5
--	---	--------------

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment**Product:**

Assessment	:	This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
------------	---	--

12.6 Other adverse effects**Product:**

Endocrine disrupting potential	:	The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
--------------------------------	---	---

SECTION 13: Disposal considerations**13.1 Waste treatment methods**

Product	:	Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal.

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.0	28.09.2024	2091173-00016	Date of first issue: 17.10.2017

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information**14.1 UN number**

ADN	:	UN 3082
ADR	:	UN 3082
RID	:	UN 3082
IMDG	:	UN 3082
IATA	:	UN 3082

14.2 UN proper shipping name

ADN	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Buparvaquone)
ADR	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Buparvaquone)
RID	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Buparvaquone)
IMDG	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Buparvaquone)
IATA	:	Environmentally hazardous substance, liquid, n.o.s. (Buparvaquone)

14.3 Transport hazard class(es)

	Class	Subsidiary risks
ADN	:	9
ADR	:	9
RID	:	9
IMDG	:	9
IATA	:	9

14.4 Packing group

ADN		
Packing group	:	III
Classification Code	:	M6
Hazard Identification Number	:	90
Labels	:	9
ADR		
Packing group	:	III
Classification Code	:	M6
Hazard Identification Number	:	90
Labels	:	9

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.0	28.09.2024	2091173-00016	Date of first issue: 17.10.2017

Tunnel restriction code : (-)

RID

Packing group	: III
Classification Code	: M6
Hazard Identification Number	: 90
Labels	: 9

IMDG

Packing group	: III
Labels	: 9
EmS Code	: F-A, S-F

IATA (Cargo)

Packing instruction (cargo aircraft)	: 964
Packing instruction (LQ)	: Y964
Packing group	: III
Labels	: Miscellaneous

IATA (Passenger)

Packing instruction (passenger aircraft)	: 964
Packing instruction (LQ)	: Y964
Packing group	: III
Labels	: Miscellaneous

14.5 Environmental hazards**ADN**

Environmentally hazardous : yes

ADR

Environmentally hazardous : yes

RID

Environmentally hazardous : yes

IMDG

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.0	28.09.2024	2091173-00016	Date of first issue: 17.10.2017

SECTION 15: Regulatory information**15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
-------------------	---	--

Full text of H-Statements

H315	:	Causes skin irritation.
H319	:	Causes serious eye irritation.
H335	:	May cause respiratory irritation.
H360D	:	May damage the unborn child.
H400	:	Very toxic to aquatic life.
H410	:	Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Aquatic Acute	:	Short-term (acute) aquatic hazard
Aquatic Chronic	:	Long-term (chronic) aquatic hazard
Eye Irrit.	:	Eye irritation
Repr.	:	Reproductive toxicity
Skin Irrit.	:	Skin irritation
STOT SE	:	Specific target organ toxicity - single exposure
2004/37/EC	:	Europe. Directive 2004/37/EC on the protection of workers from the risks related to exposure to carcinogens or mutagens at work
2009/161/EU	:	Europe. COMMISSION DIRECTIVE 2009/161/EU establishing a third list of indicative occupational exposure limit values in implementation of Council Directive 98/24/EC and amending Commission Directive 2000/39/EC
2004/37/EC / STEL	:	Short term exposure limit
2004/37/EC / TWA	:	Long term exposure limit
2009/161/EU / TWA	:	Limit Value - eight hours
2009/161/EU / STEL	:	Short term exposure limit

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regula-

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.0	28.09.2024	2091173-00016	Date of first issue: 17.10.2017

tion (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Skin Irrit. 2	H315
Eye Irrit. 2	H319
Repr. 1B	H360D
STOT SE 3	H335
Aquatic Acute 1	H400
Aquatic Chronic 1	H410

Classification procedure:

Calculation method
Calculation method
Calculation method
Calculation method
Calculation method
Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
5.0	28.09.2024	2091173-00016	Date of first issue: 17.10.2017

intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN